Cardiovascular disease (CVD) is highly prevalent and a leading cause of death among patients with chronic kidney disease (CKD).
1 Left ventricular hypertrophy and systolic and diastolic dysfunction are well-recognized indicators of worse cardiovascular outcomes in patients undergoing dialysis. In advanced CKD, the myocardium is exposed to complex metabolic stressors that result from uremia-related inflammation, oxidative stress, renin-angiotensin-aldosterone system activation, calcitriol and klotho deficiency, increased fibroblast growth factor (FGF) 23, and changes in mineral metabolism.
2 This exposure leads to myocyte hypertrophy, reduced myocardial capillarization, and nonvascularized interstitial fibrosis as well as arteriosclerosis and arterial stiffening.
3,4 Together, these ultrastructural changes reduce pump efficiency and increase cardiac energy expenditure and myocardial oxygen consumption.